These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22154769)

  • 1. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
    Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
    Tyring SK; Diaz-Mitoma F; Padget LG; Nunez M; Poland G; Cassidy WM; Bundick ND; Li J; Chan IS; Stek JE; Annunziato PW;
    Vaccine; 2007 Feb; 25(10):1877-83. PubMed ID: 17227688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
    Macaladad N; Marcano T; Guzman M; Moya J; Jurado F; Thompson M; Meechan C; Li D; Schlienger K; Chan I; Sadoff J; Schödel F; Silber JL
    Vaccine; 2007 Mar; 25(11):2139-44. PubMed ID: 17250932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
    Benson CA; Andersen JW; Macatangay BJC; Mailliard RB; Rinaldo CR; Read S; Bozzolo DR; Purdue L; Jennings C; Keefer MC; Glesby M; Tebas P; Russell AF; Martin J; Annunziato P; Popmihajlov Z; Lennox JL
    Clin Infect Dis; 2018 Nov; 67(11):1712-1719. PubMed ID: 29590326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
    Levin MJ; Smith JG; Kaufhold RM; Barber D; Hayward AR; Chan CY; Chan IS; Li DJ; Wang W; Keller PM; Shaw A; Silber JL; Schlienger K; Chalikonda I; Vessey SJ; Caulfield MJ
    J Infect Dis; 2003 Nov; 188(9):1336-44. PubMed ID: 14593591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
    Mullane KM; Winston DJ; Wertheim MS; Betts RF; Poretz DM; Camacho LH; Pergam SA; Mullane MR; Stek JE; Sterling TM; Zhao Y; Manoff SB; Annunziato PW
    J Infect Dis; 2013 Nov; 208(9):1375-85. PubMed ID: 23908479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
    Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
    J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Eberhardson M; Hall S; Papp KA; Sterling TM; Stek JE; Pang L; Zhao Y; Parrino J; Popmihajlov Z
    Clin Infect Dis; 2017 Oct; 65(7):1174-1182. PubMed ID: 29126292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
    Choi WS; Choi JH; Jung DS; Choi HJ; Kim YS; Lee J; Jang HC; Shin EC; Park JS; Kim H; Cheong HJ
    Vaccine; 2019 Jun; 37(27):3605-3610. PubMed ID: 31122860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.
    Sadaoka K; Okamoto S; Gomi Y; Tanimoto T; Ishikawa T; Yoshikawa T; Asano Y; Yamanishi K; Mori Y
    J Infect Dis; 2008 Nov; 198(9):1327-33. PubMed ID: 18774884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
    Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ
    J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA; Chen LK; Huang KC
    Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.